Early Application of Topical 15% Idoxuridine in Dimethyl Sulfoxide Shortens the Course of Herpes Simplex Labialis: A Multicenter Placebo-Controlled Trial

In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. ID...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1990-02, Vol.161 (2), p.191-197
Main Authors: Spruance, Spotswood L., Stewart, Jeffery c. B., Freeman, Donna J., Brightman, Vernon J., Cox, Jack L., Wenerstrom, Gay, McKeough, Mark B., Rowe, Nathaniel H.
Format: Article
Language:English
Subjects:
Administration, Topical
Adult
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antivirals
Biological and medical sciences
Dimethyl Sulfoxide
Double-Blind Method
Erythema
Female
Healing
Herpes labialis
Herpes Labialis - drug therapy
Herpes simplex
Humans
Idoxuridine - administration & dosage
Idoxuridine - adverse effects
Idoxuridine - therapeutic use
Lesions
Major Articles
Male
Medical sciences
Middle Aged
Multicenter Studies as Topic
Pharmacology. Drug treatments
Prospective Studies
Randomized Controlled Trials as Topic
Recurrence
Self Administration
Simplexvirus - isolation & purification
Skin
Solutions
Sulfoxides
Ulcers
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35%, P = .01)and the mean healing time to loss of crust by 1.7 days (21%, P = .004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42%, P = .OS) and the mean healing time to loss of crust by 3.3 days (3S%, P
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/161.2.191